BioSpace News Archive

Narayan is a senior scientist and group lead at the Center for Molecular Microscopy.

As a deadly mystery disease with an unknown etiology caused worldwide panic in the early 1980s and quickly became an epidemic, Dr. Jeffrey Lifson was right in the middle of it.

In 1981, Dr. Edgar Engleman, an immunologist and Director of the Stanford Blood Center learned of two patients that had been admitted to Stanford Hospital with a new disease.

More than 20 abstracts by FNL investigators will be presented in mini symposia, late-breaking research and poster sessions throughout the March 29 to April 3 meeting at the Georgia World Congress Center.

Drs. Dmitrovsky, Sharpless, and Lowy contend that the Frederick National Laboratory is a little-known entity to the cancer research community, but it “could be a great part of its discovery arsenal.”

It was produced at the Frederick National Laboratory for Cancer Research over a five-year span to meet increasing clinical demand, and it may play an ongoing role in the future of HIV research.

Samsung BioLogics recently entered a new era by signing a “first of its kind” deal with a US biopharmaceutical company valued at $7.8 million US through 2020.

Rettsyndrome.org announced their funding of two new research projects today. Jeannie T. Lee, MD, Ph.D. of Massachusetts General Hospital is awarded a two-year ANGEL Grant for $600,000 to focus on reactivating the silent X chromosome for Rett syndrome and Davut Pehlivan, MD of Baylor College of Medicine is awarded a two-year Mentored Clinical Fellowship for $250,000 to study MECP2 Duplication syndrome.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced key data from the SVS TCAR Surveillance Project and ROADSTER-2 study will be presented at the upcoming Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM), June 12-15

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it has initiated its MicroPine Phase III program with the first patient enrolled in its CHAPERONE study.